Moderna Aktie

Moderna für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A2N9D9 / ISIN: US60770K1079

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
15.09.2023 14:37:50

European Commission Authorises XBB.1.5-adapted Moderna COVID-19 Vaccine

(RTTNews) - The European Commission has authorised the Spikevax XBB.1.5-adapted COVID-19 vaccine, developed by Moderna. It is the third adaptation of this vaccine to respond to new COVID-19 variants. Moderna has adapted COVID-19 vaccine to target the SARS-CoV-2 Omicron strain XBB.1.5.

"I encourage those concerned, especially those aged 60 years and above, persons with weakened immune systems and underlying health conditions, to get their booster dose with the latest updated vaccines targeting the variants that are currently spreading as soon as possible," said Stella Kyriakides, Commissioner for Health and Food Safety.

For More Such Health News, visit rttnews.com.

Analysen zu Moderna Incmehr Analysen

19.11.24 Moderna Hold Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
13.09.24 Moderna Underweight JP Morgan Chase & Co.
05.08.24 Moderna Sector Perform RBC Capital Markets
12.01.24 Moderna Outperform RBC Capital Markets
03.11.23 Moderna Buy Goldman Sachs Group Inc.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Moderna Inc 23,70 -0,94% Moderna Inc